Publication:
Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase.

Loading...
Thumbnail Image

Date

2022-04-13

Authors

Ruiz-Huertas, Pedro
Borrego-Luque, Alicia
Toledano-Valero, Pilar
Manzotti, Carolina
Rollón-Mayordomo, Ángel

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Florid oral papillomatosis is characterized by its tendency to local recurrence that requires multiple treatments, leading to important functional sequelae. We present 74-year-old woman with oral florid papillomatosis (OFP) who refused a new surgical treatment, and was treated with imiquimod 5% in orabase on alternate days for 16 weeks. Treatment was complemented with application of hyaluronic acid gel. There were no side effects to the treatment, nor signs of local recurrence, in the treated area at 2 years of follow-up. After reviewing the literature and according to our knowledge, this is the first published case of oral florid papillomatosis treated topically with imiquimod 5% successfully. Topical treatment with imiquimod 5% in orabase may be a valid alternative for patients with recurrent OFP located in the anterior area of the oral cavity who refuse surgical treatment, although we must closely monitor the patient for the possibility of recurrence or malignant degeneration.

Description

MeSH Terms

Administration, Topical
Aged
Carboxymethylcellulose Sodium
Female
Humans
Imiquimod
Papilloma

DeCS Terms

CIE Terms

Keywords

imiquimod, immunotherapy, oral florid papillomatosis, oral mucosa

Citation